CYTOKINETICS, INCORPORATED Long-term Debt, Gross
CYTOKINETICS, INCORPORATED (CYTK) had Long-term Debt, Gross of $999.04 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentCarryingAmount · last filed 2026-02-26
- 2025-12-31: Long-term Debt, Gross $999.04M.
- 2019-03-31: Long-term Debt, Gross $42.00M.
- 2018-12-31: Long-term Debt, Gross $42.00M.
- 2018-09-30: Long-term Debt, Gross $42.00M.
| Period end | Long-term Debt, Gross |
|---|---|
| 2025-12-31 | $999.04M 10-K · filed 2026-02-26 |
| 2019-03-31 | $42.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $42.00M 10-Q · filed 2019-05-09 |
| 2018-09-30 | $42.00M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $32.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $32.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $32.00M 10-K · filed 2019-03-07 |
| 2017-09-30 | $30.00M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $30.00M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $30.00M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $30.00M 10-K · filed 2018-03-05 |
| 2016-09-30 | $30.00M 10-Q/A · filed 2016-12-15 |
| 2016-06-30 | $30.00M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $30.00M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $15.00M 10-K · filed 2017-03-06 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |